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Abstract 
Neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage 
disorders. NCLs include the rare autosomal recessive neurodegenerative disorder 
neuronal ceroid lipofuscinosis type 2 (CLN2) disease, caused by mutations in the 
tripeptidyl peptidase 1 (TPP1)/CLN2 gene and the resulting TPP1 enzyme deficiency. 
CLN2 disease most commonly presents with seizures and/or ataxia in the late-infantile 
period (ages 2-4), often in combination with a history of language delay, followed by 
progressive childhood dementia, motor and visual deterioration, and early death. Atypical 
phenotypes are characterized by later onset and, in some instances, longer life 
expectancies. Early diagnosis is important to optimize clinical care and improve 
outcomes; however, currently, delays in diagnosis are common due to low disease 
awareness, nonspecific clinical presentation, and limited access to diagnostic testing in 
some regions. In May 2015, international experts met to recommend best laboratory 
practices for early diagnosis of CLN2 disease. When clinical signs suggest an NCL, 
TPP1 enzyme activity should be among the first tests performed (together with the 
palmitoyl-protein thioesterase enzyme activity assay to rule out CLN1 disease). However, 
reaching an initial suspicion of an NCL or CLN2 disease can be challenging; thus, use of 
an epilepsy gene panel for investigation of unexplained seizures in the late-
infantile/childhood ages is encouraged. To confirm clinical suspicion of CLN2 disease, 
the recommended gold standard for laboratory diagnosis is demonstration of deficient 
TPP1 enzyme activity (in leukocytes, fibroblasts or dried blood spots) and the 
identification of causative mutations in each allele of the TPP1/CLN2 gene. When it is 
not possible to perform both analyses, either demonstration of a) deficient TPP1 enzyme 
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activity in leukocytes or fibroblasts, or b) detection of two pathogenic mutations in trans 
is diagnostic for CLN2 disease. 
Key words: Neuronal ceroid lipofuscinosis, laboratory diagnosis, lysosomal storage 
disorder, expert recommendations, neurodegeneration, genetic cause of epilepsy  
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1. Introduction  
Neuronal ceroid lipofuscinosis type 2 (CLN2) disease (OMIM 204500) is a rare 
autosomal recessive lysosomal storage disorder that results from deficient activity of the 
lysosomal exopeptidase tripeptidyl peptidase 1 (TPP1) enzyme (EC 3.4.14.9) caused by 
mutations in the TPP1/CLN2 gene (GenBank accession no. NM_000391.3) [1]. As in 
other neuronal ceroid lipofuscinosis (NCL) disorders (Table 1), CLN2 disease leads to 
intralysosomal accumulation of autofluorescent storage materials and neuronal loss.  
The in vivo substrate(s) of TPP1 are not known, and the molecular pathology of TPP1 
enzyme deficiency is poorly understood [2]. CLN2 disease incidence estimates range 
from 0.22 to 9.0 per 100,000 live births, but it is possible that it is under-recognized [2-
4]. 
 
The classic phenotype of CLN2 disease is the most common form of NCL with late-
infantile onset (roughly defined as ages 2-4 years) and generally manifests with new-
onset seizures and/or ataxia, typically in combination with a history of early language 
delay [5]. Classic phenotype disease progression is rapid, leading to the loss of acquired 
developmental milestones, new or worsening ataxia, movement disorders (myoclonus, 
dystonia, and chorea), progressive dementia, and eventual loss of vision [3, 5-9]. A 
majority of those diagnosed with CLN2 disease die prematurely after becoming 
bedridden and blind. The more rare atypical phenotypes are characterized by varied ages 
of initial presentation and/or longer life expectancy [5, 10-12]. An example of atypical 
CLN2 disease is spinocerebellar ataxia autosomal recessive 7 (SCAR7; OMIM 609270), 
which was initially described as a distinct disorder but is in fact caused by partially 
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deficient TPP1 enzyme activity; individuals with SCAR7 develop ataxia and cerebellar 
atrophy but do not develop seizures or loss of vision [12].  
 
In May 2015, 13 international laboratory and clinical NCL experts met both to develop a 
CLN2 disease–specific diagnostic algorithm (Figure 1) and to define the gold standard 
diagnostic laboratory tests to support an early and accurate diagnosis of CLN2 disease. 
 
2. Clinical suspicion and paths to diagnosis of CLN2 disease 
Developing a specific suspicion of CLN2 disease through differential diagnosis is often a 
protracted process, due in part to lack of pathognomonic signs at onset. Based on the 
expert meeting discussions, three general paths lead to a laboratory diagnosis of CLN2 
disease, depending on degree of CLN2 disease suspicion (Figure 1). 
 
2.1 High suspicion of CLN2 disease 
CLN2 disease is rarely suspected or diagnosed at initial presentation to the clinic unless 
there is already a known, affected family member. Because CLN2 disease is one of the 
most common of NCL disorders [13], children who ultimately present to an NCL 
specialist with ataxia, worsening unprovoked seizures, history of language delay and/or 
are at a developmental stand-still will follow a clear, direct, path specific for a high 
suspicion of classic CLN2 disease (Figure 1, center) [5]. Typically, diagnosis only occurs 
after a series of misdiagnoses, as the early disease course is clinically similar to many 
other seizure and/or metabolic disorders.  
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An EEG is often the first clinical test performed irrespective of the level of specific 
clinical suspicion (Figure 1). In cases of CLN2 disease, electroencephalograms (EEGs) 
may detect irregular activity, a slowing of background activity, and epileptiform 
abnormalities in posterior regions. Visual evoked potentials reveal an increase of latency; 
optical coherence tomography may detect ocular abnormalities; and electroretinograms 
may be diminished [3, 5, 8, 14, 15]. Ocular abnormalities and vision defects can be subtle 
initially but increase in prominence with disease progression [5, 8, 15].  
 
Findings of brain imaging techniques (such as magnetic resonance imaging) include 
progressive cerebellar and cerebral atrophy, reductions in grey matter volume, and 
periventricular white matter hyperintensities [8, 16-19]. It is important to recognize that 
although CLN2 is a grey matter disease, periventricular white matter hyperintensities 
may be seen and should not deviate the diagnosis path towards a leukodystrophy. These 
findings may provide clues for diagnosis. 
 
EEG with intermittent photic stimulation (IPS) performed at a frequency of 1 to 2 Hz is a 
particularly informative test. In many EEGs of patients ultimately diagnosed with CLN2 
disease a characteristic flash-per-flash response has been reported at low frequency of 
stimulation. A classical epileptiform photoparoxysmal response is usually evident at 
higher frequencies of stimulation [3, 5, 20-22]. Although IPS is often part of routine 
assessment performed in response to new-onset seizures, if performed only at frequencies 
of > 2 Hz, the characteristic response (at 1-2 Hz) that is present in many individuals with 
CLN2 disease will be missed.  Lack of a characteristic response cannot rule out CLN2 
disease, however.  
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2.2 High suspicion of an NCL disorder 
More commonly, a history of ataxia, worsening unprovoked seizures and presence of 
early language delay may not specifically be recognized as CLN2 disease but may be 
generally suggestive of an NCL disorder upon presentation to a metabolic specialist/ 
geneticist, an NCL specialist, or a pediatric neurologist with experience diagnosing NCL 
disorders. Upon a general suspicion of an NCL disorder (Figure 1, right), use of an NCL 
gene panel is endorsed to rapidly assess all known NCL genes, as most NCL gene 
products cannot readily be assessed in a biochemical assay. Equally highly recommended 
is assessment of enzyme activity of TPP1 and palmitoyl-protein thioesterase 1 (PPT1; EC 
3.1.2.22) as a screening approach, because the associated diseases (CLN2 and CLN1 
[OMIM 256730], respectively) are the most prevalent infantile and late infantile NCL 
disorders [13] and reliable enzyme activity assays exist for both. Other investigations 
may include sequential sequencing of commonly mutated NCL genes and/or use of 
electron microscopy (EM) to assess the accumulation of intracellular storage materials, 
which is a general hallmark of the NCL disorders [13, 23-28]. 
 
2.3 High suspicion of genetic basis for epilepsy/neurological symptoms  
Most commonly, initial presentation of ataxia and/or unprovoked seizures and a history 
of a language delay to a pediatrician or even to a pediatric neurologist, results in no 
specific suspicion of CLN2 disease or NCL.  Seizures are a relatively common symptom 
that prompts medical consultation in young children ranging from 1-14% of children 
under 5 years globally depending on region [29-31].  As part of the investigation into the 
etiology of epileptic seizures, there is increasing evidence to support use of a gene panel 
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to disclose a genetic basis of epilepsy for childhood, late-infantile, or particularly 
infantile epileptic seizures.  Therefore, at this stage, the clinician (Figure 1, left) may 
order a gene panel directed to epilepsy and seizure disorders [32-35]. Whole exome and 
whole genome sequencing may also be considered to uncover a previously 
uncharacterized genetic basis of epilepsy.  
 
2.4 Differential diagnosis of CLN2 disease 
Different epilepsy syndromes may be considered in young children with new-onset 
seizures, including: Ohtahara, West, Dravet, and Lennox-Gastaut, myoclonic-astatic 
epilepsy/MAE (Doose syndrome), and Landau-Kleffner syndromes. GLUT1 deficiency, 
benign myoclonic epilepsies, progressive myoclonic epilepsies (Lafora disease, 
Unverricht-Lundborg disease, myoclonic epilepsy with ragged-red fibers), along with 
other channelopathies and metabolic syndromes that are associated with myoclonic 
epilepsy (including sialidoses and galactosialidosis) also may be considered.  
 
Epilepsy and progressive neurodegeneration in children should raise suspicion of not 
only NCL, but also for gangliosidoses, mucopolysaccharidoses, mucolipidoses, Niemann-
Pick type C disease, peroxisomal disorders, mitochondrial disorders, Gaucher disease 
type III, and leukodystrophies.  
 
While many of these disorders and syndromes are in fact distinguishable from the classic 
presentation of CLN2 disease, natural variation in clinical presentation of these disorders 
and syndromes often conceals an early and direct path to diagnosis of CLN2 disease. 
Distinguishing between these disorders and syndromes is difficult as many lack 
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biochemical diagnostic tests, such as enzyme activity tests and/or biomarker tests, 
slowing the time to diagnosis. Fortunately, there is a biochemical test for diagnosis of 
CLN2 disease. 
 
3. Laboratory diagnostic tests for CLN2 disease 
3.1 TPP1 enzyme activity analysis 
CLN2 disease is diagnosable by a biochemical test of TPP1.  TPP1 enzyme is a pepstatin-
insensitive lysosomal serine exopeptidase with optimal in vitro activity at acidic pH [1, 
36-38]. Although a tandem mass spectrometry (MS) compatible substrate was recently 
developed [39], most diagnostic laboratories assess TPP1 enzyme activity using the 
fluorogenic substrate, Ala-Ala-Phe-7-amido-4-methylcoumarin [37, 38, 40]. Several 
variations on the fluorogenic methodology have been published [41-43], each of which 
can differentiate affected individuals from healthy controls; however, the absolute 
activities differ. Therefore, it is essential that laboratories carefully establish unaffected 
reference ranges for their implementation of the TPP1 enzyme assay (Figure 2).  
 
Leukocytes isolated from whole blood are the recommended sample type for analysis of 
TPP1 enzyme activity, enabling accurate and rapid diagnostic analysis.  Multiple 
laboratories report TPP1 enzyme activity levels measured in affected individuals to be 
distinct from carriers and unaffected individuals (although the absolute activities differ; 
Figure 2). However, whole blood samples are particularly sensitive to exposure to 
temperature extremes or to delays in shipping and receipt, potentially reducing assay 
reliability. 
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In addition to leukocytes, several other sample types may be used for analysis of TPP1 
enzyme activity, such as fibroblasts, dried blood spots (DBS), and saliva. The TPP1 
enzyme assay should be separately validated for each sample type in which it is 
performed. Although analysis of TPP1 enzyme activity in fibroblasts requires culture of a 
skin punch biopsy, leading to delays in diagnostic testing, skin punch biopsies are more 
robust in suboptimal shipment conditions than whole-blood samples. DBS samples are of 
great use in regions where the timely and appropriate shipment of blood and/or tissue 
samples is problematic and is the likely sample of choice for any screening approaches to 
detect CLN2 disease [39], although appropriate DBS sample collection, drying, and 
timely shipment remain important for DBS samples. Evaluation of TPP1 enzyme activity 
in saliva samples [44] is a component of an integrated strategy for diagnosis of NCL 
disorders in Latin America [10, 26].  
 
Appropriate control enzymes are essential to accurately interpret TPP1 enzyme activity 
findings. PPT1 is a suitable control enzyme because it has broadly similar stability as the 
TPP1 enzyme in DBS [45], and the experience of most investigators is that the stabilities 
are comparable in leukocytes, fibroblasts, and saliva. Additionally, evaluation of PPT1 
enzyme activity serves a dual function to both assess sample quality and exclude CLN1 
disease, another NCL disorder that can initially present with seizures at similar ages as 
those with CLN2 disease. An additional appropriate control enzyme is β-galactosidase 
(EC 3.2.1.23), a lysosomal enzyme not associated with an NCL disorder.  Currently, the 
only other lysosomal enzyme defect associated with NCL disease, and for which a 
specific clinical test is available, is cathepsin D (CLN10 disease).  Whereas, the 
remainder of the NCL disorders are not due to an enzyme deficiency.  
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3.2 Electron microscopy (EM) analysis 
Accumulation of intracellular storage materials in neuronal and non-neuronal cells is a 
morphological hallmark of the NCL disorders. Historically, detection of intracellular 
storage materials by EM has been an important technique for the classification and 
diagnosis of NCL disorders [46]. The recent increase in availability of molecular testing 
has limited the use of EM studies in the diagnosis and differentiation of NCL disorders 
[23]. In addition, few laboratories now have the required expertise for the accurate 
interpretation of electron micrographs. 
 
Clinical EM investigation of those suspected of having an NCL disorder typically 
requires collection of skin biopsies or blood samples: rectal, skeletal muscle, and 
conjunctival biopsies can also be used [23]. EM examination shows accumulation of 
storage materials, typically with curvilinear profiles in CLN2 disease. Some CLN2 
disease biopsies show a mixed pattern of both curvilinear and fingerprint profiles, a 
pattern that may be associated with atypical CLN2 phenotypes [10, 23, 28].   
 
3.3 Molecular analysis of TPP1/CLN2 
A diagnosis of CLN2 disease can be confirmed by identification of two pathogenic 
variants/mutations (associated with a TPP1 enzyme deficiency) in trans in the 
TPP1/CLN2 gene. The TPP1/CLN2 gene is located on chromosome 11p15 [47], contains 
13 exons, and is 6.7 kb in length. As of March 2016, 140 changes in the TPP1/CLN2 
gene have been reported, of which 116 are reported to be pathogenic [13, 28, 48]. 
Globally, the two most commonly reported mutations associated with CLN2 disease are 
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c.509-1G>C, a splicing mutation, and c.622C>T (p.Arg208Ter), which results in the 
introduction of a premature termination codon [13, 28, 49, 50] (Figure 3). However, in 
one laboratory’s experience, these two alleles have not been identified during diagnosis 
of individuals of Southeast Asian or Middle Eastern origin (M. Fietz, written 
communication, April 2016), indicating that c.509-1G>C and c.622C>T (p.Arg208Ter) 
are not common in all populations. Further, different mutation profiles have been 
reported in some locations, such as Argentina [10, 25, 26] and Canada/Newfoundland, 
where a founder effect mutation has been well characterized [28, 51, 52]. Consequently, 
global allele frequencies are not necessarily relevant for some local diagnostic purposes. 
 
Given the broad range of mutations that have been associated with CLN2 disease [13, 
28], sequencing of the TPP1/CLN2 gene should ideally evaluate the entire coding region 
and associated intron-exon splice junctions. If DNA sequencing fails to identify 
mutations, other approaches such as mRNA analysis, array comparative genome 
hybridization (aCGH), deletion/duplication analyses, and whole genome/exome 
sequencing may be of use. If two pathogenic mutations in the TPP1/CLN2 gene are 
identified, it is important to confirm that they are on separate parental alleles (i.e., in 
trans); analysis of parental DNA samples can clarify the phase of the detected mutations. 
Analysis of parental DNA can also detect possible allele dropout and subsequent false 
assessments of homozygosity. De novo mutations that arise in germ cells are also 
possible, although this has not been reported to date. It has been the experience of the 
authors that both TPP1/CLN2 mutations are generally identified by DNA sequencing and, 
to date, few large deletions have been identified in individuals with CLN2 disease.  In 
cases where one TPP1/CLN2 gene pathogenic variant/ mutation is uncovered in 
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molecular testing, enzyme activity testing is warranted as detection of only one 
pathogenic variant cannot rule out CLN2 disease.   
 
As with other recessive genetic disorders, molecular analysis may identify variants of 
unknown significance (VUS). At present, the number of reported VUS and likely non-
pathogenic sequence changes in the TPP1/CLN2 gene is relatively low: of 140 reported 
sequence alterations, 24 alterations (17%) are not believed to be pathogenic [13, 48]. 
However, it is likely that not all detected VUS have been reported. The increasing use of 
molecular testing in suspected cases of CLN2 disease may increase the number of VUS. 
Again, if two pathogenic mutations in trans are not identified, diagnostic testing of TPP1 
enzyme activity is required. 
 
3.4 Gene panels and whole exome/genome sequencing 
Relevant gene panels—such as symptom-based (epilepsy) gene panels, NCL gene panels, 
lysosomal disorder or inherited metabolic disorder gene panels—may speed the 
diagnostic process when CLN2 disease is not specifically suspected. Key strengths of 
gene panels include relatively rapid turnaround time, the assessment of many genetic 
conditions in one analysis, and the investigation of genetic conditions that are not 
diagnosed through enzyme activity assays as mentioned. An informal survey of US 
laboratories offering gene panels suggests that the TPP1/CLN2 gene is present on many 
gene panels, including those targeting NCL disorders, epilepsy, neurology, lysosomal 
storage disorders, inherited metabolic disorders, and eye disorders. The authors 
recommend the use of gene panels given the support they can provide clinicians in 
moving rapidly from clinical presentation to a laboratory diagnosis.  
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Whole exome/genome sequencing (WEGS) approaches share many of the strengths of 
gene panels and have the advantage of examining far more of the genome, albeit with an 
accompanying increase in data complexity and analysis requirements. WEGS approaches 
may be of particular use for identification of novel diseases or if the clinical 
manifestation of a given mutation is outside of a gene’s known disease spectrum, as was 
the case for the TPP1/CLN2 mutations found to cause SCAR7 disease [12]. However, not 
all regions will have access or support for WEGS approaches and the cost and turn-
around-time relative to a gene panel is typically higher and longer. 
 
 
4. Conclusions 
In early stages, CLN2 disease is challenging to recognize, and diagnosis is often delayed 
until after the disease has progressed significantly. In the majority of cases, key initial 
symptoms are new-onset epileptic seizures in combination with a history of early 
language delay and/or ataxia, although alternative presentations are possible [5]. 
Differential diagnosis of a genetic basis of epilepsy by use of symptom- or disease-based 
gene panels offer great promise for supporting an early and timely diagnosis of not only 
CLN2 disease but many other causes of late-infantile epilepsy as well. In absence of 
newborn screening for CLN2 disease, gene panels are the broadest symptom-based, 
multiple-disease screening approach with a reasonable diagnostic yield. Laboratory tests 
to diagnose CLN2 disease are well established. TPP1 enzyme activity can be assessed in 
several sample types: leukocytes, DBS, fibroblasts, and saliva. The gold standard for 
laboratory diagnosis is demonstration of deficient TPP1 enzyme activity (in conjunction 
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with normal activity of a control enzyme such as PPT1 and/or β-galactosidase) followed 
by molecular analysis that detects one pathogenic mutation on each parental allele of 
TPP1/CLN2. Given the availability of reliable enzyme activity assays for both TPP1 and 
PPT1, together with the higher prevalence of the NCL disorders for which TPP1 or PPT1 
activity is lost (CLN2 disease and CLN1 disease, respectively [13]), we recommend that 
the activity of each enzyme be assayed early in any individual suspected of having an 
NCL disorder. Future prospects for early diagnosis include ongoing development of MS-
compatible enzyme substrates [39], which could support large-scale screening approaches 
such as newborn screening. Disease-specific management, genetic counseling, and new 
therapies in development for CLN2 disease make early and accurate diagnosis of this 
severe neurodegenerative disease essential.  
 
Acknowledgments 
The authors thank all 18 respondents to the CLN2 Disease Expert Survey and all 
attendees of the CLN2 Expert Meeting, held May 2015 in Prague, Czech Republic, both 
of which were organized and supported by BioMarin Pharmaceutical Inc. The authors 
also thank Mitch Bailey, MS, Elaina Jurecki, MS, RD, and Renee Shediac, PhD, of 
BioMarin Pharmaceutical Inc for review of the manuscript and the Batten Disease 
Support and Research Association for sharing patient family survey information. This 
article was prepared with editorial assistance from Karl Zawadzki, PhD, of Health 
Interactions, which was funded by BioMarin Pharmaceutical Inc. 
 
Author contributions 
All authors were involved in the conception, drafting, and review of this manuscript.  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
17 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
 
References 
[1] D.E. Sleat, R.J. Donnelly, H. Lackland, C.G. Liu, I. Sohar, R.K. Pullarkat, P. Lobel, 
Association of mutations in a lysosomal protein with classical late-infantile neuronal 
ceroid lipofuscinosis, Science 277 (1997) 1802-1805. 
[2] J.D. Cooper, M.A. Tarczyluk, H.R. Nelvagal, Towards a new understanding of NCL 
pathogenesis, Biochim.Biophys.Acta 1852 (2015) 2256-2261. 
[3] S.E. Mole, R.E. Williams, H.H. Goebel, (Eds), The neuronal ceroid lipofuscinoses 
(Batten disease) (2011). 
[4] N.A. Simpson, E.D. Wheeler, D.A. Pearce, Screening, diagnosis and epidemiology of 
Batten disease, Expert Opinion on Orphan Drugs 2 (2014) 903-910. 
[5] A. Schulz, S.E. Mole, J.L. Cohen-Pfeffer, R. Crystal, E. De Los Reyes, Y. Eto, M.J. 
Fietz, B. Héron, C. Keyes, C.M. Lourenço, N. Miller, I. Noher de Halac, D.A. 
Pearce, M.S. Perez-Poyato, A. Simonati, A. Kohlschütter, CLN2 disease: natural 
history, challenges in clinical recognition and path to diagnosis, In preparation 
(2016). 
[6] M.S. Perez-Poyato, M.P. Marfa, I.F. Abizanda, L. Rodriguez-Revenga, V.C. Sanchez, 
M.J. Gonzalez, J.E. Punal, A.V. Perez, M.M. Gonzalez, A.M. Bermejo, E.M. 
Hernandez, M.J. Rosell, L. Gort, M. Mila, Late infantile neuronal ceroid 
lipofuscinosis: mutations in the CLN2 gene and clinical course in Spanish patients, 
J.Child Neurol. 28 (2013) 470-478. 
[7] R. Steinfeld, P. Heim, H. von Gregory, K. Meyer, K. Ullrich, H.H. Goebel, A. 
Kohlschutter, Late infantile neuronal ceroid lipofuscinosis: quantitative description 
of the clinical course in patients with CLN2 mutations, Am.J.Med.Genet. 112 (2002) 
347-354. 
[8] S. Worgall, M.V. Kekatpure, L. Heier, D. Ballon, J.P. Dyke, D. Shungu, X. Mao, B. 
Kosofsky, M.G. Kaplitt, M.M. Souweidane, D. Sondhi, N.R. Hackett, C. Hollmann, 
R.G. Crystal, Neurological deterioration in late infantile neuronal ceroid 
lipofuscinosis, Neurology 69 (2007) 521-535. 
[9] S.E. Mole, R.E. Williams, Neuronal ceroid-lipofuscinoses., in : R.A. Pagon, M.P. 
Adam, H.H. Ardinger (Eds.), GeneReviews®, Seattle, WA, 2001, updated 2013. 
[10] R. Kohan, F. Pesaola, N. Guelbert, P. Pons, A.M. Oller-Ramirez, G. Rautenberg, A. 
Becerra, K. Sims, W. Xin, I.A. Cismondi, I. Noher de Halac, The neuronal ceroid 
lipofuscinoses program: A translational research experience in Argentina, 
Biochim.Biophys.Acta 1852 (2015) 2301-2311. 
[11] R. Di Giacopo, L. Cianetti, V. Caputo, I. La Torraca, F. Piemonte, A. Ciolfi, S. 
Petrucci, C. Carta, P. Mariotti, V. Leuzzi, E.M. Valente, A. D'Amico, A. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
19 
 
Bentivoglio, E. Bertini, M. Tartaglia, G. Zampino, Protracted late infantile ceroid 
lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical 
characterization in three sibs, J.Neurol.Sci. 356 (2015) 65-71. 
[12] Y. Sun, R. Almomani, G.J. Breedveld, G.W. Santen, E. Aten, D.J. Lefeber, J.I. Hoff, 
E. Brusse, F.W. Verheijen, R.M. Verdijk, M. Kriek, B. Oostra, M.H. Breuning, M. 
Losekoot, J.T. den Dunnen, B.P. van de Warrenburg, A.J. Maat-Kievit, Autosomal 
recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene 
involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 
disease), Hum.Mutat. 34 (2013) 706-713. 
[13] S.E. Mole, S.L. Cotman, Genetics of the neuronal ceroid lipofuscinoses (Batten 
disease), Biochim.Biophys.Acta 1852 (2015) 2237-2241. 
[14] A. Schulz, A. Kohlschütter, J. Mink, A. Simonati, R. Williams, NCL diseases — 
clinical perspectives, Biochimica et Biophysica Acta (BBA) - Molecular Basis of 
Disease 1832 (2013) 1801-1806. 
[15] A. Orlin, D. Sondhi, M.T. Witmer, M.M. Wessel, J.G. Mezey, S.M. Kaminsky, N.R. 
Hackett, K. Yohay, B. Kosofsky, M.M. Souweidane, M.G. Kaplitt, D.J. D'Amico, 
R.G. Crystal, S. Kiss, Spectrum of ocular manifestations in CLN2-associated batten 
(Jansky-Bielschowsky) disease correlate with advancing age and deteriorating 
neurological function, PLoS One 8 (2013) e73128. 
[16] J.P. Dyke, H.U. Voss, D. Sondhi, N.R. Hackett, S. Worgall, L.A. Heier, B.E. 
Kosofsky, A.M. Ulug, D.C. Shungu, X. Mao, R.G. Crystal, D. Ballon, Assessing 
disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR 
diffusion-weighted imaging, AJNR Am.J.Neuroradiol. 28 (2007) 1232-1236. 
[17] J.P. Dyke, D. Sondhi, H.U. Voss, D.C. Shungu, X. Mao, K. Yohay, S. Worgall, N.R. 
Hackett, C. Hollmann, M.E. Yeotsas, A.L. Jeong, B. Van de Graaf, I. Cao, S.M. 
Kaminsky, L.A. Heier, K.D. Rudser, M.M. Souweidane, M.G. Kaplitt, B. Kosofsky, 
R.G. Crystal, D. Ballon, Assessment of disease severity in late infantile neuronal 
ceroid lipofuscinosis using multiparametric MR imaging, AJNR Am.J.Neuroradiol. 
34 (2013) 884-889. 
[18] P. Santavuori, S.L. Vanhanen, T. Autti, Clinical and neuroradiological diagnostic 
aspects of neuronal ceroid lipofuscinoses disorders, Eur.J.Paediatr.Neurol. 5 Suppl A 
(2001) 157-161. 
[19] T. Autti, R. Raininko, P. Santavuori, S.L. Vanhanen, V.P. Poutanen, M. Haltia, MRI 
of neuronal ceroid lipofuscinosis. II. Postmortem MRI and histopathological study of 
the brain in 16 cases of neuronal ceroid lipofuscinosis of juvenile or late infantile 
type, Neuroradiology 39 (1997) 371-377. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
20 
 
[20] S. Binelli, L. Canafoglia, F. Panzica, A. Pozzi, S. Franceschetti, 
Electroencephalographic features in a series of patients with neuronal ceroid 
lipofuscinoses, Neurol.Sci. 21 (2000) S83-7. 
[21] E. Veneselli, R. Biancheri, M.V. Perrone, S. Buoni, A. Fois, Neuronal ceroid 
lipofuscinoses: clinical and EEG findings in a large study of Italian cases, 
Neurol.Sci. 21 (2000) S75-81. 
[22] D.V. Albert, H. Yin, E. De Los Reyes, J. Vidaurre, Unique characteristics of the 
photoparoxysmal response in patients with neuronal ceroid lipofuscinosis type 2: can 
EEG be a biomarker?, American Epilepsy Society Annual Meeting, www.aesnet.org 
Abstract No 1.037 (2015). 
[23] G.W. Anderson, H.H. Goebel, A. Simonati, Human pathology in NCL, 
Biochim.Biophys.Acta 1832 (2013) 1807-1826. 
[24] H.H. Goebel, Morphological aspects of the neuronal ceroid lipofuscinoses, 
Neurol.Sci. 21 (2000) S27-33. 
[25] R. Kohan, M.N. Carabelos, W. Xin, K. Sims, N. Guelbert, I.A. Cismondi, P. Pons, 
G.I. Alonso, M. Troncoso, S. Witting, D.A. Pearce, R. Dodelson de Kremer, A.M. 
Oller-Ramirez, I. Noher de Halac, Neuronal ceroid lipofuscinosis type CLN2: a new 
rationale for the construction of phenotypic subgroups based on a survey of 25 cases 
in South America, Gene 516 (2013) 114-121. 
[26] R. Kohan, I.A. Cismondi, R.D. Kremer, V.J. Muller, N. Guelbert, V.T. Anzolini, 
M.J. Fietz, A.M. Ramirez, I. Noher de Halac, An integrated strategy for the 
diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven 
Latin American patients, Clin.Genet. 76 (2009) 372-382. 
[27] A. Simonati, N. Rizzuto, Neuronal ceroid lipofuscinoses: pathological features of 
bioptic specimens from 28 patients, Neurol.Sci. 21 (2000) S63-70. 
[28] M. Kousi, A.E. Lehesjoki, S.E. Mole, Update of the mutation spectrum and clinical 
correlations of over 360 mutations in eight genes that underlie the neuronal ceroid 
lipofuscinoses, Hum.Mutat. 33 (2012) 42-63. 
[29] W.A. Hauser, The prevalence and incidence of convulsive disorders in children, 
Epilepsia 35 Suppl 2 (1994) S1-6. 
[30] P.E. Waaler, B.H. Blom, H. Skeidsvoll, A. Mykletun, Prevalence, classification, and 
severity of epilepsy in children in western Norway, Epilepsia 41 (2000) 802-810. 
[31] S.A. Russ, K. Larson, N. Halfon, A national profile of childhood epilepsy and 
seizure disorder, Pediatrics 129 (2012) 256-264. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
21 
 
[32] I.E. Scheffer, Epilepsy genetics revolutionizes clinical practice, Neuropediatrics 45 
(2014) 70-74. 
[33] H.C. Mefford, Clinical Genetic Testing in Epilepsy, Epilepsy Curr. 15 (2015) 197-
201. 
[34] K.L. Helbig, K.D. Farwell Hagman, D.N. Shinde, C. Mroske, Z. Powis, S. Li, S. 
Tang, I. Helbig, Diagnostic exome sequencing provides a molecular diagnosis for a 
significant proportion of patients with epilepsy, Genet.Med. (2016). 
[35] J. Wang, G. Gotway, J.M. Pascual, J.Y. Park, Diagnostic yield of clinical next-
generation sequencing panels for epilepsy, JAMA Neurol. 71 (2014) 650-651. 
[36] I. Sohar, D.E. Sleat, M. Jadot, P. Lobel, Biochemical characterization of a lysosomal 
protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) 
and development of an enzyme-based assay for diagnosis and exclusion of LINCL in 
human specimens and animal models, J.Neurochem. 73 (1999) 700-711. 
[37] D. Vines, M.J. Warburton, Purification and characterisation of a tripeptidyl 
aminopeptidase I from rat spleen, Biochim.Biophys.Acta 1384 (1998) 233-242. 
[38] D.J. Vines, M.J. Warburton, Classical late infantile neuronal ceroid lipofuscinosis 
fibroblasts are deficient in lysosomal tripeptidyl peptidase I, FEBS Lett. 443 (1999) 
131-135. 
[39] M. Barcenas, C. Xue, T. Marushchak-Vlaskin, C.R. Scott, M.H. Gelb, F. Turecek, 
Tandem mass spectrometry assays of palmitoyl protein thioesterase 1 and tripeptidyl 
peptidase activity in dried blood spots for the detection of neuronal ceroid 
lipofuscinoses in newborns, Anal.Chem. 86 (2014) 7962-7968. 
[40] I. Sohar, L. Lin, P. Lobel, Enzyme-based diagnosis of classical late infantile 
neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-
insensitive protease assays, Clin.Chem. 46 (2000) 1005-1008. 
[41] E.P. Young, B.G. Winchester, W. Peter Logan, R.B. Wheeler, B.D. Lake, Exclusion 
of late infantile neuronal ceroid lipofuscinosis (LINCL) in a fetus by assay of 
tripeptidyl peptidase I in chorionic villi, Prenat.Diagn. 20 (2000) 337-339. 
[42] O.P. Van Diggelen, J.L. Keulemans, W.J. Kleijer, S. Thobois, C. Tilikete, Y.V. 
Voznyi, Pre- and postnatal enzyme analysis for infantile, late infantile and adult 
neuronal ceroid lipofuscinosis (CLN1 and CLN2), Eur.J.Paediatr.Neurol. 5 Suppl A 
(2001) 189-192. 
[43] V.J. Muller, B.C. Paton, M.J. Fietz, An Australasian diagnostic service for the 
neuronal ceroid lipofuscinoses, Eur.J.Paediatr.Neurol. 5 Suppl A (2001) 197-201. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
22 
 
[44] R. Kohan, I. Noher de Halac, V. Tapia Anzolini, A. Cismondi, A.M. Oller Ramirez, 
A. Paschini Capra, R.D. de Kremer, Palmitoyl Protein Thioesterase1 (PPT1) and 
Tripeptidyl Peptidase-I (TPP-I) are expressed in the human saliva. A reliable and 
non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) 
neuronal ceroid lipofuscinoses, Clin.Biochem. 38 (2005) 492-494. 
[45] Z. Lukacs, P. Santavuori, A. Keil, R. Steinfeld, A. Kohlschutter, Rapid and simple 
assay for the determination of tripeptidyl peptidase and palmitoyl protein 
thioesterase activities in dried blood spots, Clin.Chem. 49 (2003) 509-511. 
[46] J. Radke, W. Stenzel, H.H. Goebel, Human NCL Neuropathology, 
Biochim.Biophys.Acta 1852 (2015) 2262-2266. 
[47] J.L. Haines, R.M. Boustany, J. Alroy, K.J. Auger, K.S. Shook, H. Terwedow, T.J. 
Lerner, Chromosomal localization of two genes underlying late-infantile neuronal 
ceroid lipofuscinosis, Neurogenetics 1 (1998) 217-222. 
[48] S.E. Mole, NCL mutation and patient 
database, http://www.ucl.ac.uk/ncl/mutation 2016. 
[49] N. Zhong, K.E. Wisniewski, J. Hartikainen, W. Ju, D.N. Moroziewicz, L. 
McLendon, S.S. Sklower Brooks, W.T. Brown, Two common mutations in the 
CLN2 gene underlie late infantile neuronal ceroid lipofuscinosis, Clin.Genet. 54 
(1998) 234-238. 
[50] D.E. Sleat, R.M. Gin, I. Sohar, K. Wisniewski, S. Sklower-Brooks, R.K. Pullarkat, 
D.N. Palmer, T.J. Lerner, R.M. Boustany, P. Uldall, A.N. Siakotos, R.J. Donnelly, P. 
Lobel, Mutational analysis of the defective protease in classic late-infantile neuronal 
ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder, 
Am.J.Hum.Genet. 64 (1999) 1511-1523. 
[51] S.J. Moore, D.J. Buckley, A. MacMillan, H.D. Marshall, L. Steele, P.N. Ray, Z. 
Nawaz, B. Baskin, M. Frecker, S.M. Carr, E. Ives, P.S. Parfrey, The clinical and 
genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland, 
Clin.Genet. 74 (2008) 213-222. 
[52] W. Ju, R. Zhong, S. Moore, D. Moroziewicz, J.R. Currie, P. Parfrey, W.T. Brown, 
N. Zhong, Identification of novel CLN2 mutations shows Canadian specific NCL2 
alleles, J.Med.Genet. 39 (2002) 822-825. 
  
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
23 
 
Table 1. The neuronal ceroid lipofuscinosis disorders 
Age and clinical presentation     Genes 
 
Protein products, in bold if enzyme assay 
widely available 
Classical clinical 
presentation by age 
group 
Newborns (through infantile)     
• Epilepsy 
• Microcephaly 
 CLN1 PPT1 (lysosomal lipid hydrolase) Classical 
 CLN10 CtsD (lysosomal peptidase) Classical 
 
CLN14 
KCTD7 (unknown function; homology to 
potassium channel tetramerization domain)  
Classical 
Young children (late infantile)     
• Developmental delay or 
regression 
• Newly occurring epilepsy of 
unknown cause 
 CLN1 PPT1 (lysosomal lipid hydrolase)  
 CLN2 TPP1 (lysosomal exopeptidase) Classical 
 CLN5 (soluble lysosomal protein) Classical  
 CLN6 (transmembrane protein) Classical 
 CLN7 MFSD8 (transmembrane protein) Classical 
 CLN8 (transmembrane protein) Classical  
 CLN10 CtsD (lysosomal peptidase)  
School-aged children (juvenile)  
 
  
• Vision loss 
• Dementia 
• Epilepsy 
 CLN1 PPT1 (lysosomal lipid hydrolase)  
 CLN2 TPP1 (lysosomal exopeptidase)  
 CLN3 (transmembrane protein) Classical  
 CLN5 (soluble lysosomal protein)  
 CLN6 (transmembrane protein)   
 CLN7 MFSD8 (transmembrane protein)  
 CLN8 (transmembrane protein)  
 CLN10 CtsD (lysosomal peptidase)  
 CLN12 ATP13A2 (ATPase) Classical 
Young adults  
 
  
• Nonspecific mental, motor, or 
behavioral abnormalities 
 CLN1 PPT1 (lysosomal lipid hydrolase)  
 CLN2 TPP1 (lysosomal exopeptidase)  
 CLN4  
(autosomal dominant) 
DNAJC5 (HSP40/DNAJ protein) Classical 
 CLN5 (soluble lysosomal protein)  
 CLN6 (transmembrane protein)  
  CLN10 CtsD (lysosomal peptidase)  
  CLN11 GRN (progranulin) Classical 
  CLN13 CtsF (lysosomal proteinase) Classical 
Adapted from the DEM-CHILD algorithm, http://www.dem-child.eu/index.php/ncl-
diagnostic-algorithm.html, and Schulz et al 2013 [14].  
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CLN, neuronal ceroid lipofuscinosis; Cts, cathepsin; GRN, granulin; HSP40, heat shock 
protein 40; KCTD7, potassium channel tetramerization domain containing 7; MFSD8, 
major facilitator superfamily domain containing 8; PPT1, palmitoyl-protein thioesterase 
1; TPP1, tripeptidyl peptidase 1. 
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Table 2. Roles of recommended investigations in the diagnosis of CLN2 disease 
 
Nature Test 
Sample 
type(s) 
Considerations Role in diagnosis 
Clinical 
test 
EEG with IPS 
at 1 to 2 Hz 
N/A 
Individuals with CLN2 disease have 
characteristic EEG posterior spikes in 
response to each light flash (at 1-2 Hz) [5] 
NCL disorders other than CLN2 disease 
may present with these characteristic 
responses 
Note that IPS is often routinely performed 
at > 2 Hz, which will not elicit these 
characteristic responses 
Not a diagnostic test 
Electron 
microscopy 
Detection of 
intracellular 
storage bodies 
Typically 
skin, rectal, 
or blood 
samples 
Accurate assessment and interpretation 
require experience and specialized skills 
that are not widely available 
Findings may not be unique to a specific 
NCL 
Not sufficient for diagnosis of a 
specific NCL disorder 
Enzyme 
assay 
TPP1 enzyme 
activity assay 
DBS or 
saliva 
Always assess activity of ≥ 1 enzyme in 
addition to TPP1 (PPT1 and/or β-
galactosidase recommended) 
Deficient TPP1 activity in DBS or 
saliva is diagnostic if confirmed by 
molecular analysis 
Enzyme 
assay 
TPP1 enzyme 
activity assay 
Leukocytes 
or 
fibroblasts 
Always assess activity of ≥ 1 enzyme in 
addition to TPP1 (PPT1 and/or β-
galactosidase recommended) 
Deficient TPP1 activity in 
leukocytes or fibroblasts is 
diagnostic if consistent with clinical 
presentation 
To confirm a diagnosis, molecular 
analysis is recommended 
Molecular 
analysis 
Gene panels 
containing the 
TPP1/CLN2 
gene 
Typically 
blood, 
buccal 
swabs, or 
saliva; 
other 
samples 
possible 
Does not require specific suspicion of 
CLN2 disease, potentially speeding path to 
diagnosis 
Sanger sequencing is recommended to 
confirm identified mutations 
Access and reimbursement can vary 
regionally 
Analysis of parental DNA samples may 
clarify whether detected alterations are in 
trans or in cis 
Not all detected alterations may be readily 
interpretable, and in rare cases, both 
causative mutations may not be identified 
Findings not diagnostic unless test 
is validated for diagnosis 
If validated: a finding of 2 
pathogenic mutations consistent 
with clinical presentation in trans is 
diagnostic 
To confirm a diagnosis, enzyme 
analysis is necessary if only 1 
pathogenic variant is found, no 
variant is found, or if 1 or more 
VUS is identified 
Molecular 
analysis 
TPP1/CLN2 
gene 
sequencing 
Typically 
blood, 
buccal 
swabs, or 
saliva; 
other 
samples 
possible 
Sequencing of all exons and associated 
intron-exon junctions recommended 
Analysis of parental DNA samples may 
clarify whether detected alterations are in 
trans or in cis 
Not all detected alterations may be readily 
interpretable, and in rare cases, both 
causative mutations may not be identified 
A finding of 2 pathogenic 
mutations consistent with clinical 
presentation in trans is diagnostic 
To confirm a diagnosis, enzyme 
analysis is necessary if only 1 
pathogenic variant is found, no 
variant is found, or if 1 or more 
VUS is identified 
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CLN2, neuronal ceroid lipofuscinosis 2; DBS, dried blood spot; EEG, electroencephalogram; IPS, intermittent photic 
stimulation; N/A, not applicable; PPT1, palmitoyl-protein thioesterase 1; TPP1, tripeptidyl peptidase 1; VUS, variant of 
unknown/uncertain significance.  
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Figure legends 
Figure 1. Diagnostic algorithm in support of early suspicion and diagnosis of neuronal 
ceroid lipofuscinosis type 2 (CLN2) disease. CLN2 disease is diagnosed by biochemical 
and molecular laboratory tests. Unexplained seizures, particularly when associated with a 
history of unexplained language delay and/or developmental milestone regression, may 
be caused by a neuronal ceroid lipofuscinosis (NCL) disorder; another common possible 
early symptom is ataxia. Electroencephalography (EEG) analysis under specific 
intermittent photic stimulation (IPS; 1-2 Hz) may assist with differential diagnoses. The 
recommended approach once CLN2 disease is specifically suspected (center) is 
demonstration of deficient tripeptidyl peptidase 1 (TPP1) enzyme activity in leukocytes 
together with the identification of 2 pathogenic mutations in the TPP1/CLN2 gene. When 
an NCL disorder is suspected (right), an NCL gene panel and/or TPP1 enzyme screening 
along with palmitoyl-protein thioesterase 1 (PPT1) enzyme screening is recommended. 
When the main suspicion is broadly of a genetic basis of epilepsy (left), a gene panel to 
investigate genetic causes of childhood-onset epilepsy is recommended. CLN2 disease 
diagnosis is achieved upon demonstration of deficient TPP1 enzyme activity in 
leukocytes together with normal activity of ≥ 1 appropriate control enzyme (such as 
PPT1 and/or β-galactosidase) and identification of 2 pathogenic mutations in trans in the 
TPP1/CLN2 gene.  
EM, electron microscopy; ERG, electroretinography; FA, fluorescein angiography; MRI, 
magnetic resonance imaging; OCT, optical coherence tomography; VEP, visually evoked 
potential. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
28 
 
Figure 2. Enzyme activity ranges of tripeptidyl peptidase 1 (TPP1) in leukocytes 
observed in 5 independent laboratories. Activity ranges for healthy individuals (wild type 
[WT]), carriers, and affected individuals (with neuronal ceroid lipofuscinosis type 2 
[CLN2] disease) are reported. Although the absolute enzyme activities differ among the 
laboratories (likely due to methodological differences, such as the protease inhibitors 
used and the assay pH), each individual laboratory clearly differentiates the TPP1 
enzyme activity of individuals with CLN2 disease from that of unaffected controls.  
 
Figure 3. Mutations associated with classic neuronal ceroid lipofuscinosis type 2 (CLN2) 
disease. Five mutations in the tripeptidyl peptidase 1 (TPP1)/CLN2 gene have been 
reported > 10 times [28]. The mutations c.509-1G>C and c.622C>T (p.Arg208Ter) 
together represent 57% of all reported mutations (reported by Kousi et al [28]), and ≥ 1 of 
these 2 alleles is present in 69% to 89% of those diagnosed with CLN2 disease [28, 49, 
50].   
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Highlights for “Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 
disease): expert recommendations for early detection and laboratory 
diagnosis” 
3-5 bullets, 85 characters max (including spaces) per bullet 
 CLN2 disease is a rare pediatric autosomal recessive lysosomal storage 
disorder 
 Early diagnosis is important but delays are common 
 A group of international experts met to improve recognition and diagnosis 
 Initial symptoms are generally seizures, ataxia, and/or a history of language 
delay 
 Laboratory diagnosis is from deficient enzyme activity and/or molecular 
analysis 
